Recent contemporary advances in the treatment of obesity and diabetes has also guided the development of co‐agonistic approaches to drug therapy such as GLP‐1/glucagon, glucose‐dependent insulinotropic polypeptide (GIP)–GLP1, amylin–calcitonin dual agonists, and GIP–GLP1–glucagon tri‐agonists.185. Here, CALCA is linked to obesity disorder.